卡波西肉瘤相关疱疹病毒与宿主免疫在卡波西肉瘤发病中的作用机制及免疫治疗

国际肿瘤学杂志››2021,Vol. 48››Issue (6): 377-380.doi:10.3760/cma.j.cn371439-20200923-00073

卡波西肉瘤相关疱疹病毒与宿主免疫在卡波西肉瘤发病中的作用机制及免疫治疗

王芳, 王鹏, 康晓静()

新疆维吾尔自治区人民医院皮肤性病科新疆皮肤病研究重点实验室,乌鲁木齐 830001

收稿日期:2020-09-23修回日期:2020-10-16出版日期:2021-06-08发布日期:2021-06-24
通讯作者:康晓静 E-mail:drkangxj666@163.com
基金资助:
新疆维吾尔自治区创新环境(人才、基地)建设专项“天山创新团队计划”(2020D14006)

Mechanism and immunotherapy of Kaposi sarcoma-associated herpesvirus and host immunity in the pathogenesis of Kaposi sarcoma

Wang Fang, Wang Peng, Kang Xiaojing()

Department of Dermatology, People's Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Key Laboratory of Dermatology Research, Urumqi 830001, China

Received:2020-09-23Revised:2020-10-16Online:2021-06-08Published:2021-06-24
Contact:Kang Xiaojing E-mail:drkangxj666@163.com
Supported by:
Xinjiang Uygur Autonomous Region Innovation Environmen (Talent,Base) Construction Project “Tianshan Innovation Team Plan” of China(2020D14006)

摘要/Abstract

摘要：

卡波西肉瘤是一种软组织多发性色素性血管瘤,其病因尚不明确,其发生发展与卡波西肉瘤相关疱疹病毒相关。卡波西肉瘤相关疱疹病毒可通过干扰模式识别受体、补体系统或直接作用于免疫细胞逃避宿主免疫系统,从而在卡波西肉瘤的发生与发展中起重要作用,免疫调节剂、靶向药物及疫苗等免疫治疗有望成为预防及治疗卡波西肉瘤的新方法。

关键词:肉瘤,卡波西,卡波西肉瘤相关疱疹病毒,宿主免疫,免疫治疗

Abstract:

Kaposi sarcoma is a multiple pigmented hemangioma of soft tissue. The etiology of Kaposi sarcoma is still unclear. Its occurrence is related to Kaposi sarcoma-related herpesvirus. Kaposi sarcoma-associated herpes virus plays an important role in the occurrence and development of Kaposi sarcoma by interfering with the pattern recognition receptors, complement system, or effecting on the immune cells directly to evasive host immune system. The immune modulators, immunotherapy of targeted drugs and vaccines are expected to be the new methods for the prevention and treatment of Kaposi sarcoma.

Key words:Sarcoma,Kaposi,Kaposi sarcoma-associated herpesvirus,Host immune,Immunotherapy

王芳, 王鹏, 康晓静. 卡波西肉瘤相关疱疹病毒与宿主免疫在卡波西肉瘤发病中的作用机制及免疫治疗[J]. 国际肿瘤学杂志, 2021, 48(6): 377-380.

Wang Fang, Wang Peng, Kang Xiaojing. Mechanism and immunotherapy of Kaposi sarcoma-associated herpesvirus and host immunity in the pathogenesis of Kaposi sarcoma[J]. Journal of International Oncology, 2021, 48(6): 377-380.

参考文献32

[1]	Yarchoan R, Uldrick TS. HIV-associated cancers and related diseases[J]. N Engl J Med, 2018,378(11):1029-1041. DOI: 10.1056/NEJMra1615896. doi:10.1056/NEJMra1615896
[2]	Cesarman E, Damania B, Krown SE, et al. Kaposi sarcoma[J]. Nat Rev Dis Primers, 2019,5(1):9. DOI: 10.1038/s41572-019-0060-9. doi:10.1038/s41572-019-0060-9pmid:30705286
[3]	Wong JP, Damania B. Modulation of oncogenic signaling networks by Kaposi's sarcoma-associated herpesvirus[J]. Biol Chem, 2017,398(8):911-918. DOI: 10.1515/hsz-2017-0101. doi:10.1515/hsz-2017-0101
[4]	Zhang H, Ni G, Damania B. ADAR1 facilitates KSHV lytic reactivation by modulating the RLR-dependent signaling pathway[J]. Cell Rep, 2020,31(4):107564. DOI: 10.1016/j.celrep.2020.107564. doi:10.1016/j.celrep.2020.107564
[5]	Broussard G, Damania B. KSHV: immune modulation and immunotherapy[J]. Front Immunol, 2020,10:3084. DOI: 10.3389/fimmu.2019.03084. doi:10.3389/fimmu.2019.03084
[6]	Uppal T, Sarkar R, Dhelaria R, et al. Role of pattern recognition receptors in KSHV infection[J]. Cancers (Basel), 2018,10(3):85. DOI: 10.3390/cancers10030085. doi:10.3390/cancers10030085
[7]	Sharma NR, Majerciak V, Kruhlak MJ, et al. KSHV inhibits stress granule formation by viral ORF57 blocking PKR activation[J]. PLoS Pathog, 2017,13(10):e1006677. DOI: 10.1371/journal.ppat.1006677. doi:10.1371/journal.ppat.1006677
[8]	Griffin C, Eter L, Lanzetta N, et al. TLR4, TRIF, and MyD88 are essential for myelopoiesis and CD11c⁺adipose tissue macrophage production in obese mice [J]. J Biol Chem, 2018,293(23):8775-8786. DOI: 10.1074/jbc.RA117.001526. doi:10.1074/jbc.RA117.001526
[9]	Lee HR, Amatya R, Jung JU. Multi-step regulation of innate immune signaling by Kaposi's sarcoma-associated herpesvirus[J]. Virus Res, 2015,209:39-44. DOI: 10.1016/j.virusres.2015.03.004. doi:10.1016/j.virusres.2015.03.004
[10]	Zhao Q, Liang D, Sun R, et al. Kaposi's sarcoma-associated herpesvirus-encoded replication and transcription activator impairs innate immunity via ubiquitin-mediated degradation of myeloid differentiation factor 88[J]. J Virol, 2015,89(1):415-427. DOI: 10.1128/JVI.02591-14. doi:10.1128/JVI.02591-14
[11]	Lingel A, Ehlers E, Wang Q, et al. Kaposi's sarcoma-associated herpesvirus reduces cellular myeloid differentiation primary-response gene 88 (MyD88) expression via modulation of its RNA[J]. J Virol, 2016,90(1):180-188. DOI: 10.1128/JVI.02342-15. doi:10.1128/JVI.02342-15
[12]	Rex DAB, Agarwal N, Prasad TSK, et al. A comprehensive pathway map of IL-18-mediated signalling[J]. J Cell Commun Signal, 2020,14(2):257-266. DOI: 10.1007/s12079-019-00544-4. doi:10.1007/s12079-019-00544-4pmid:31863285
[13]	Ma Z, Hopcraft SE, Yang F, et al. NLRX1 negatively modulates type Ⅰ IFN to facilitate KSHV reactivation from latency[J]. PLoS Pathog, 2017,13(5):e1006350. DOI: 10.1371/journal.ppat.1006350. doi:10.1371/journal.ppat.1006350
[14]	Baillet N, Krieger S, Carnec X, et al. E3 ligase ITCH interacts with the z matrix protein of lassa and mopeia viruses and is required for the release of infectious particles[J]. Viruses, 2019,12(1):49. DOI: 10.3390/v12010049. doi:10.3390/v12010049
[15]	Zhang G, Chan B, Samarina N, et al. Cytoplasmic isoforms of Kaposi sarcoma herpesvirus lana recruit and antagonize the innate immune DNA sensor cGAS[J]. Proc Natl Acad Sci U S A, 2016,113(8):E1034-E1043. DOI: 10.1073/pnas.1516812113. doi:10.1073/pnas.1516812113
[16]	Subramanian G, Kuzmanovic T, Zhang Y, et al. A new mechanism of interferon's antiviral action: induction of autophagy, essential for paramyxovirus replication, is inhibited by the interferon stimulated gene, TDRD7[J]. PLoS Pathog, 2018,14(1):e1006877. DOI: 10.1371/journal.ppat.1006877. doi:10.1371/journal.ppat.1006877
[17]	Manes TD, Hoer S, Muller WA, et al. Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins block distinct steps in transendo-thelial migration of effector memory CD4⁺T cells by targeting diffe-rent endothelial proteins [J]. J Immunol, 2010,184(9):5186-5192. DOI: 10.4049/jimmunol.0902938. doi:10.4049/jimmunol.0902938
[18]	Qin J, Li W, Gao SJ, et al. KSHV microRNAs: tricks of the devil[J]. Trends Microbiol, 2017,25(8):648-661. DOI: 10.1016/j.tim.2017.02.002. doi:10.1016/j.tim.2017.02.002
[19]	De Pelsmaeker S, Romero N, Vitale M, et al. Herpesvirus evasion of natural killer cells[J]. J Virol, 2018,92(11):e02105-e02117. DOI: 10.1128/JVI.02105-17.
[20]	Lee MS, Jones T, Song DY, et al. Exploitation of the complement system by oncogenic Kaposi's sarcoma-associated herpesvirus for cell survival and persistent infection[J]. PLoS Pathog, 2014,10(9):e1004412. DOI: 10.1371/journal.ppat.1004412. doi:10.1371/journal.ppat.1004412
[21]	Jeon H, Yoo SM, Choi HS, et al. Extracellular vesicles from kshv-infected endothelial cells activate the complement system[J]. Oncotarget, 2017,8(59):99841-99860. DOI: 10.18632/oncotarget.21668. doi:10.18632/oncotarget.v8i59
[22]	Yoo SM, Lee MS. Kaposi's sarcoma-associated herpesvirus and host interaction by the complement system[J]. Pathogens, 2020,9(4):260. DOI: 10.3390/pathogens9040260. doi:10.3390/pathogens9040260
[23]	Davis DA, Mishra S, Anagho HA, et al. Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide[J]. Oncotarget, 2017,8(31):50342-50358. DOI: 10.18632/oncotarget.17960. doi:10.18632/oncotarget.v8i31
[24]	Polizzotto MN, Uldrick TS, Wyvill KM, et al. Pomalidomide for symptomatic Kaposi's sarcoma in people with and without HIV infection: a phase Ⅰ/Ⅱ study[J]. J Clin Oncol, 2016,34(34):4125-4131. DOI: 10.1200/JCO.2016.69.3812. doi:10.1200/JCO.2016.69.3812
[25]	Lingel H, Brunner-Weinzierl MC. CTLA-4 (CD152): a versatile receptor for immune-based therapy[J]. Semin Immunol, 2019,42:101298. DOI: 10.1016/j.smim.2019.101298. doi:10.1016/j.smim.2019.101298
[26]	Dupin N. Update on oncogenesis and therapy for Kaposi sarcoma[J]. Curr Opin Oncol, 2020,32(2):122-128. DOI: 10.1097/CCO.0000000000000601. doi:10.1097/CCO.0000000000000601
[27]	Host KM, Jacobs SR, West JA, et al. Kaposi's sarcoma-associated herpesvirus increases PD-L1 and proinflammatory cytokine expression in human monocytes[J]. mBio, 2017,8(5):e00917. DOI: 10.1128/mBio.00917-17.
[28]	Galanina N, Goodman AM, Cohen PR, et al. Successful treatment of HIV-associated Kaposi sarcoma with immune checkpoint blockade[J]. Cancer Immunol Res, 2018,6(10):1129-1135. DOI: 10.1158/2326-6066.CIR-18-0121. doi:10.1158/2326-6066.CIR-18-0121pmid:30194084
[29]	Fujiwara Y, Sun Y, Torphy RJ, et al. Pomalidomide inhibits PD-L1 induction to promote antitumor immunity[J]. Cancer Res, 2018,78(23):6655-6665. DOI: 10.1158/0008-5472.CAN-18-1781. doi:10.1158/0008-5472.CAN-18-1781
[30]	Uldrick TS, Goncalves PH, Abdul-Hay M, et al. Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer—a phase 1 study[J]. JAMA Oncol, 2019,5(9):1332-1339. DOI: 10.1001/jamaoncol.2019.2244. doi:10.1001/jamaoncol.2019.2244
[31]	Barasa AK, Ye P, Phelps M, et al. BALB/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8.1, gB, and gH/gL induced comparable serum neutralizing antibody activity to UV-inactivated KSHV[J]. Oncotarget, 2017,8(21):34481-34497. DOI: 10.18632/oncotarget.15605. doi:10.18632/oncotarget.15605pmid:28404899
[32]	Mulama DH, Mutsvunguma LZ, Totonchy J, et al. A multivalent Kaposi sarcoma-associated herpesvirus-like particle vaccine capable of eliciting high titers of neutralizing antibodies in immunized rabbits[J]. Vaccine, 2019,37(30):4184-4194. DOI: 10.1016/j.vaccine.2019.04.071. doi:S0264-410X(19)30559-6pmid:31201053